SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Social media discourse surrounding SpaceX is currently dominated by warnings about illegitimate crypto tokens impersonating the company ahead of a rumored future IPO. While some users express genuine interest in tracking the company's valuation through related space sector ETFs and proxies, the community is heavily focused on labeling these tokenized 'pre-stocks' as potential scams and rug pulls.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is generating significant buzz as investors weigh the company's aggressive AI and cloud infrastructure pivot against upcoming earnings and high-stakes geopolitical trade talks. While the community is split between bullish sentiment over long-term AI potential and skepticism surrounding recent earnings volatility, attention is heavily focused on whether institutional positioning will trigger a re-rating for the stock.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is trending as the community highlights its AI-native infrastructure, with recent activity fueled by platform developments and rumors of a potential buyout. Investors are actively discussing the token's long-term utility in the Base ecosystem and debating whether current market price action offers an accumulation opportunity or signs of manipulation.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies is drawing significant investor interest due to its pivot toward a vertically integrated U.S. supply chain for critical minerals and rare earth magnets, which community members view as a strategic hedge against international trade tensions. While some participants are wary of potential volatility and bot activity, the stock is currently trending on the back of news regarding infrastructure expansion and institutional investment, fueling speculation about its long-term role in domestic industrial independence.

Lowe's Companies, Inc. engages in the retail sale of home improvement products. The firm offers products for maintenance, repair, remodeling, home decorating, and property maintenance. It also provides home improvement products in the following categories: appliances, seasonal & outdoor living, lumber, lawn & garden, kitchens & bath, hardware, building materials, millwork, paint, rough plumbing, tools, electrical, flooring, and décor. The company was founded in 1946 and is headquartered in Mooresville, NC.

Lowe`s Cos., Inc.

Lowe's Companies, Inc.

Lowe's Companies, Inc. is trending as investors digest a mix of analyst upgrades and downgrades while monitoring the stock's performance ahead of its upcoming earnings report. The community remains focused on how the home improvement sector, particularly Lowe's and Home Depot, will navigate broader macroeconomic headwinds and fluctuating interest rates.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is currently trending due to the completed enrollment of its Phase 3 SENTRY trial for myelofibrosis, though community discussion remains deeply polarized by frustration over persistent financial instability and long-standing concerns regarding executive leadership. Investors are actively debating the potential for a clinical turnaround against the backdrop of an extended cash runway and the company's challenging historical performance.

Harvest Portfolios Group Inc - Harvest Canadian High Income Shares ETF

Harvest Canadian High Income Shares ETF

Investors are closely monitoring the ETF's performance in light of news regarding its underlying major holdings and are actively discussing the benefits of dividend compounding through monthly distributions. The community is focused on the fund's resilience during broader market fluctuations, often weighing its strategy of maintaining exposure to leading Canadian companies.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is currently trending as investors focus on its RNA-based pipeline and the potential for strategic M&A following GSK's decision to return rights for its AATD candidate. The community is actively discussing the stock's long-term potential in the obesity market, with significant attention on upcoming trial data readouts and how the company's muscle-sparing approach compares to current GLP-1 standards.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

UniSwap is generating intense community discussion due to the 'UNIfication' governance proposal, which focuses on activating a fee switch to reward token holders and initiating a massive token burn to reduce supply. Traders are closely monitoring these potential tokenomic shifts, viewing them as a critical catalyst for long-term sustainability and value appreciation.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is seeing significant community interest driven by its strategic acquisition of Covelya Group, which bolsters its subsea technology platform, and heightened geopolitical focus on critical underwater infrastructure protection. Investors are actively discussing the company's long-term defense sector role, its potential for major exchange uplisting, and strong revenue growth outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 233 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $228.18, for a total value of $53,165.94. Following the transaction, the chief operating officer owned 4,517...

Mark Jacobson Sells 4,517 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 4,517 shares of the firm's stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $227.94, for a total transaction of $1,029,604.98. Following the sale, the chief operating officer...

AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales

Axsome posts a wider Q1 loss but revenues jump 57%, driven by strong Auvelity and Sunosi sales.

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Morgan Stanley upped their price target on Axsome Therapeutics from $217.00 to $242.00 and gave the company an 'equal weight' rating in a report on Tuesday...

Wells Fargo & Company Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $255.00

Wells Fargo & Company upped their price objective on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company an 'overweight' rating in a research note on Tuesday...

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $310.00 at Mizuho

Mizuho increased their target price on Axsome Therapeutics from $228.00 to $310.00 and gave the company an 'outperform' rating in a report on Tuesday...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twenty-one brokerages that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eighteen h...

<ul class="summary-bullets"><li>Tsai stated that Auvelity’s Q1 sales of $153 million exceeded consensus estimates for major depressive disorder.</li><li>The analyst believes the 2026 revenue estimate of $805 million for Auvelity is achievable, driven in part by a potential label expansion into Alzheimer’s agitation, which could boost sales in the second half of the year.</li><li>Deutsche Bank analyst David Hoang hiked his price target for Axsome, citing a positive outlook for Auvelity’s commercial launch and growth potential.</li></ul>Axsome Therapeutics Inc. (AXSM) reported a mixed first quarter on Monday, but analysts on Wall Street remain optimistic about the company’s prospects.According to TheFly, Jefferies analyst Andrew Tsai hiked the firm’s price target for Axsome to $275 from $245 while keeping a ‘Buy’ rating. The new price target implies an upside potential of nearly 21% from current levels.<a href="https://stocktwits.com/symbol/AXSM">Axsome Therapeutics shares</a> were up more than 10% in Monday morning’s trade. AXSM was among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">Why Is Wall Street Bullish?</h2>Tsai stated that Auvelity’s Q1 sales of $153 million exceeded consensus estimates for major depressive disorder. The analyst believes the 2026 revenue estimate of $805 million for Auvelity is achievable, driven in part by a potential label expansion into Alzheimer’s agitation, which could boost sales in the second half of the year.Auvelity is Axsome’s treatment for agitation associated with dementia due to Alzheimer’s disease. Auvelity received a “clean label” approval from the U.S. Food and Drug Administration (FDA) last week, meaning that Auvelity will not carry a warning for increased risk of death in elderly patients with dementia.According to analysts at TD Cowen, this differentiates Auvelity from the only other approved therapy for ADA, Rexulti.Deutsche Bank analyst David Hoang raised the firm’s price target on Axsome Therapeutics to $281 from $245 and maintained a ‘Buy’ rating. Hoang cited a positive outlook for Auvelity’s commercial launch and growth potential as the reason for the price target hike.H.C. Wainwright analysts raised the firm’s price target on Axsome Therapeutics to $270 from $250 and maintained a ‘Buy’ rating, citing the FDA approval of Auvelity.<h2 class="st-heading-2">What Is Auvelity?</h2>Auvelity is an oral therapy targeting NMDA and sigma-1 receptors, having been approved in the U.S. for major depressive disorder and, more recently, for agitation associated with Alzheimer’s-related dementia.The company stated that about 223,000 prescriptions were written in Q1 2026, up 35% year-on-year and in line with fourth-quarter (Q4) levels. Axsome stated that payer coverage reached roughly 86% overall, including 78% in commercial plans and full coverage in Medicare and Medicaid.Following its FDA approval last week for Alzheimer’s agitation, the drug is set for a commercial launch in June. The company has also completed an expansion of its sales force to around 630 representatives, targeting a wide range of prescribers to support growth in both depression and Alzheimer’s-related use.<h2 class="st-heading-2">Axsome’s Mixed Q1</h2>Axsome Therapeutics’ Q1 results came in mixed on Monday. The company reported a loss of $1.26 per share, while Wall Street expected a loss of $0.86 per share, according to Fiscal.ai data.Axsome’s revenue came in at $191.2 million, edging past Wall Street’s estimates of $190.7 million.According to Koyfin data, the average 12-month price target for AXSM is $235.85, implying an upside of nearly 4% from current levels. Of the 20 analysts covering the stock, 19 have a ‘Buy’ or a ‘Strong Buy’ rating, while one has a ‘Hold’ recommendation.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AXSM">Axsome Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘high’ levels at the time of writing.One bullish user expects Auvelity sales to reach at least $1.2 billion by the end of this year.<stembedurl>https://stocktwits.com/Georgejj/message/652182986</stembedurl>Another user thinks that big pharmaceutical companies are more willing than ever to acquire Axsome Therapeutics.<stembedurl>https://stocktwits.com/CloudMatt/message/652181828</stembedurl><a href="https://stocktwits.com/symbol/AXSM">AXSM stock</a> is up 24% year-to-date and 102% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 27% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 38%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fnma-stock-in-focus-mizuho-fannie-mae-best-business-one-could-hope-for/cZQMvMpReJX">Mizuho Believes Fannie Mae Is Among The Best Businesses One Could Hope For — But Not Everyone Agrees</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Axsome Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism?

Jefferies analyst Andrew Tsai hiked the firm’s price target for Axsome to $275 from $245 while keeping a ‘Buy’ rating, implying an upside potential of nearly 21% from current levels.

Equity

Axsome Therapeutics Q1 Earnings Call Highlights

Axsome Therapeutics (NASDAQ:AXSM) reported first-quarter 2026 results highlighting strong year-over-year revenue growth, a major new FDA approval for Auvelity, and continued advancement across its neuroscience pipeline. Management also detailed commercial investments to support an upcoming launch in...

Axsome Therapeutics (NASDAQ:AXSM) Reaches New 12-Month High Following Analyst Upgrade

Axsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week High After Analyst Upgrade...

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

AXSM
Axsome Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AXSM News

AXSMAxsome Therapeutics Inc